Coya to start open-label extension of ALSTARS Phase 2/3 for COYA 302, delays FTD trial to 2027
Coya plans to start an open-label extension of its Phase 2/3 ALSTARS trial for COYA 302 in November 2026, delaying its FTD trial to 2027. The company expects its cash runway to extend into the second half of 2027, according to its SEC filing.
How this was made
The 30-second read
Why it matters
The news provides fresh insight into Coya's development timeline, affecting short‑term price expectations.
Market read
First disclosure of trial extension; modest trading impact expected until data readout.
What to watch
Potential for additional funding rounds or partnership announcements tied to the extended trial.
Background
Coya Therapeutics filed an 8‑K on Oct 14 2026 detailing the trial extension and timeline shift.
Ticker impact
Coya Therapeutics announced an open‑label extension of its ALSTARS Phase 2/3 trial and delayed the FTD Phase 2 trial to 2027, a first‑time disclosure.
modest downside as investors await longer‑term data and the delayed FTD trial reduces near‑term upside
Trial extensions are typically viewed as a delay in commercialization, while longer data can be positive but only after readout.
Market effects
May signal slower pipeline progress for ALS therapeutics, affecting peer biotech valuations.
Limited to US biotech investors; no broader regional effect.
Low; relevance confined to specialty biotech space.
Counterpoint
Long‑term investors could view the extended data collection as a catalyst for a future upside if results are positive.
Key entities
- companyCoya Therapeutics, Inc.
US‑listed biotech developing ALS and FTD therapies.
